Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hong Ghi | - |
dc.contributor.author | Kim, Sung-Yong | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Kim, Yeo-Kyeoung | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Shim, Hyeok | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Park, Byeong-Bae | - |
dc.contributor.author | Lee, Junglim | - |
dc.contributor.author | Park, Sung Kyu | - |
dc.contributor.author | Cheong, June-Won | - |
dc.contributor.author | Park, Keon Woo | - |
dc.date.accessioned | 2022-07-15T21:10:12Z | - |
dc.date.available | 2022-07-15T21:10:12Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156462 | - |
dc.description.abstract | Background Among the currently available prognostic models for diffuse large B-cell lymphoma (DLBCL), we investigated to determine which is most adoptable for DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by upfront autologous stem cell transplantation (auto-SCT). Methods We retrospectively evaluated survival differences among risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI), and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT. Results At the time of auto-SCT, 74.6% and 25.4% of patients had achieved complete remission and partial remission after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) rates were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to the IPI, aaIPI, R-IPI, and NCCN-IPI did not significantly differ among the risk groups for each prognostic model (P-values for OS: 0.255, 0.337, 0.881, and 0.803, respectively; P-values for PFS: 0.177, 0.904, 0.295, and 0.609, respectively). Conclusion There was no ideal prognostic model among those currently available for CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC HEMATOLOGY | - |
dc.title | Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Byeong-Bae | - |
dc.identifier.doi | 10.5045/br.2015.50.3.160 | - |
dc.identifier.scopusid | 2-s2.0-84944050675 | - |
dc.identifier.bibliographicCitation | BLOOD RESEARCH, v.50, no.3, pp.160 - 166 | - |
dc.relation.isPartOf | BLOOD RESEARCH | - |
dc.citation.title | BLOOD RESEARCH | - |
dc.citation.volume | 50 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 160 | - |
dc.citation.endPage | 166 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002029903 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | Hematopoietic stem cell transplantation | - |
dc.subject.keywordAuthor | Autologous transplantation | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordAuthor | Prognostic groups | - |
dc.identifier.url | https://synapse.koreamed.org/articles/1092211 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.